References
- Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7–14
- Verweij PE, Donnelly FP, Kullberg BJ, et al. Amphotericin B versus amphotericin B plus 5-fluorocytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 1994; 22: 81–85
- Leenders ACAP, Daenen S, Jansen RLH, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Brit J Haematol 1998; 103: 205–212
- Ellis M, Spence D, DePauw B, et al. An EORTC International multicenter randomized trial (EORTC Number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406–1412
- Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl Med. 2002; 347: 408–415
- Patterson TF, Boucher HW, Herbrecht R, et al. The strategy of following voriconazole versus amphotericin B with other licensed antifungal therapy for primary therapy of invasive aspergillosis: Impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448–1452
- Bennett JE. Salvage therapy for aspergillosis. Clin Infect Dis 2005; 41(Suppl): S387–S388
- Bennett JE, Powers J, DePauw B, et al. Forum Report: Issues in the design of drug trials for invasive aspergillosis. Clin Infect Dis 2003; 36(Suppl): S113–S116